Mycoplasma pneumoniae accounts for up to 40% of the total number of community-acquired
pneumonias (CAP) in children and up to 20% of the pediatric CAP requiring hospitalization. M.
pneumoniae infection has a wide range of clinical manifestations from asymptomatic to severe
pneumonia requiring ICU admission. Despite the high prevalence of M. pneumoniae infections
in children, reports on severe life-threatening pneumonia caused by M. pneumoniae in children
are limited in the U.S. We identified 8 children with diverse microbiome by 16S rRNA gene
based PCR test and RNA-sequencing to evaluate the clinical outcome of severely ill children
with M. pneumoniae infection.
We hypothesize that children with M. pneumoniae infection and other co-infections like Ureaplasma will show poor clinical outcomes compared to children with M. pneumoniae infection only.
We conducted a case-control study of severally ill children aged 31 days to 17 years with respiratory failure requiring mechanical ventilation (>72h) on a multicenter study in the USA. The study includes mechanically ventilated children admitted to the 8 pediatric intensive care units (PICU) in the National Institute of Child Health and Human Development’s Collaborative Pediatric Critical Care Research Network (CPCCRN) from February 2015 to December 2017. 8 patient cases were matched to 17 controls with age (+/- 1 yr) and most abundant pathogens at the genus level. Length of PICU stay, Vent free days at 23 days, Pediatric Logistic Organ Dysfunction (PELOD-2) score, Pediatric Risk of Mortality (PRISM) score and change in The Functional Status Score (FSS) were defined as the primary measures of outcome.
Currently we are running an antimicrobial resistance (AMR) pipeline that implements the Resistance Gene Indentifier (RGI) tool for AMR sequence detection. The pipeline compares our mNGS reads against the Comprehensive Antibiotic Resistance Database (CARD). We will use 95 the AMR data along with our primary measures of outcome to compare clinical outcomes of children with M. pneumoniae infection vs other infections.
While we still have to the run analysis on our data, we predict significant difference in clinical outcome of children with M. pneumoniae compared to children with other co-infections. Our brief report will further support the need to consider atypical respiratory pathogens in future diagnostic investigations.
We hypothesize that children with M. pneumoniae infection and other co-infections like Ureaplasma will show poor clinical outcomes compared to children with M. pneumoniae infection only.
We conducted a case-control study of severally ill children aged 31 days to 17 years with respiratory failure requiring mechanical ventilation (>72h) on a multicenter study in the USA. The study includes mechanically ventilated children admitted to the 8 pediatric intensive care units (PICU) in the National Institute of Child Health and Human Development’s Collaborative Pediatric Critical Care Research Network (CPCCRN) from February 2015 to December 2017. 8 patient cases were matched to 17 controls with age (+/- 1 yr) and most abundant pathogens at the genus level. Length of PICU stay, Vent free days at 23 days, Pediatric Logistic Organ Dysfunction (PELOD-2) score, Pediatric Risk of Mortality (PRISM) score and change in The Functional Status Score (FSS) were defined as the primary measures of outcome.
Currently we are running an antimicrobial resistance (AMR) pipeline that implements the Resistance Gene Indentifier (RGI) tool for AMR sequence detection. The pipeline compares our mNGS reads against the Comprehensive Antibiotic Resistance Database (CARD). We will use 95 the AMR data along with our primary measures of outcome to compare clinical outcomes of children with M. pneumoniae infection vs other infections.
While we still have to the run analysis on our data, we predict significant difference in clinical outcome of children with M. pneumoniae compared to children with other co-infections. Our brief report will further support the need to consider atypical respiratory pathogens in future diagnostic investigations.